Specialized tests are typically performed on breast tissue obtained by a biopsy to determine whether or not the breast tumor is “hormone receptor- positive” or “hormone receptor-negative.” If it is found to be “hormone receptor-positive” therapies that inhibit the body’s ability to make estrogen, also referred as an estrogen inhibitor, are typically used to treat that particular form of breast cancer.
There are three different classes or types of estrogen inhibitors used to treat “hormone receptor-positive” breast cancer. These Include:
Aromatase Inhibitors: These therapies are typically given to women who have already gone through menopause because they actually are not able to stop the ovaries from making estrogen. Aromatase inhibitor therapies work by preventing the body from making estradiol, a form of estrogen. Arimidex (anastrazole), Aromasin (exemestane) and Femara (letrozole) are three types of aromatase inhibitors used to treat breast cancer. One significant side effect from these medications is the development of bone loss, which increases a woman’s chance of breaking a bone.
Tamoxifen: Used for more than 30 years to treat breast cancer, tamoxifen is given orally to block the activity of estrogen. Tamoxifen is used to treat women who are diagnosed with early-stage breast cancer as well as in women who have metastatic disease, meaning the breast cancer has spread to other parts of the body such as the bone, liver or lung. Research also has shown that tamoxifen helps prevent the recurrence of breast cancer and helps to prevent the development of breast cancer in women who are at high-risk of developing the disease.
LH-RH Agonists: These types of drugs, which are given by injection, include therapies such as leuprolide and goserelin. These therapies work to prevent the ovaries from making estrogen.